Inicio › Cáncer de endometrio › Texas
Ensayos clínicos de Cáncer de endometrio en Texas
95 estudios sobre Cáncer de endometrio buscan participantes en Texas.
Ciudades en Texas
- Houston69 estudios
- San Antonio27 estudios
- Dallas25 estudios
- Austin15 estudios
- Fort Worth11 estudios
- Tyler6 estudios
- Irving6 estudios
- Killeen4 estudios
- Arlington3 estudios
- Abilene3 estudios
Texto oficial del estudio (inglés)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern Clinical Center at Richardson/Plano, Richardson
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT05112601A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT07664735A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- y 2 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06270706A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 16 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07197554Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT04683653A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Hendrick Medical Center, Abilene
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Lyndon Baines Johnson General Hospital, Houston
- y 2 más
ReclutandoFase 2
Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- M.D. Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 12 nov 2026 · NCT05640999A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Texas Oncology, P.A., Tyler
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 10 nov 2026 · NCT06340568A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07020221A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Texas Oncology - DFW ( Site 8004), Fort Worth
- Houston Methodist Hospital ( Site 6057), Houston
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 10 nov 2026 · NCT06952504A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Austin, Austin
- START Dallas Fort Worth, LLC, Fort Worth
- MD Anderson, Houston
- y 4 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07503808A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- SCRI at Mary Crowley, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06515613A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
ReclutandoFase 1
Edades de 19 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06586957Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Total Women's Care of the Heights, Houston
- Medical Colleagues of Texas, LLP, Katy
ReclutandoEstudio observacional
Edades de 18 en adelante · Mujeres · Actualizado el 5 nov 2026 · NCT05051722Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- y 3 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07114601A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06760819A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06695845Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- University of Texas Southwestern Medical Center, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05856981Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- TX Onc - Arlington North, Arlington
- USOR - Texas Oncology, Austin
- USOR - Texas Oncology, Austin
- y 14 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 3 nov 2026 · NCT07166094A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- GSK Investigational Site, Sugar Land
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 3 nov 2026 · NCT07286331CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Austin
- Clinical Study Site, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07909031Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07524322EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- START Dallas Fort Worth, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07262619Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology-West Texas, Amarillo
- Texas Oncology - Central South, Austin
- y 13 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 30 oct 2026 · NCT07578649A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- MD Anderson, Houston
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- MD Anderson Cancer Center, Houston
- START Center for Cancer Research, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT07109726A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06242470A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- Texas Oncology - Bedford, Bedford
- Texas Oncology San Antonio Medical Center, San Antonio
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 27 oct 2026 · NCT07022483A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06330064A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT06172478Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- NEXT Oncology Dallas, Irving
- Texas Tech University Health Sciences Center, Lubbock
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07807345A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- NEXT Austin, Austin
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07383506A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT04657068Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT06239194Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06293898A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT05123482DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Austin
- Research Site, Fort Worth
- Research Site, Houston
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Mujeres · Actualizado el 13 oct 2026 · NCT06989112De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.